By vgreene, 5 October, 2016 Assess low bone density/fx risk factors.1-3 ✓BMD +/- vertebral imaging
By vgreene, 5 October, 2016 Reassessment nbsp nbsp NOF ASBMR Reassess BMD in all pts q2 3y 6 12 but use shorter interval if new fx or if accelerated bone loss anticipated e g due to GC aromatase inhibitor tx 12 nbsp nbsp ES 14 Reassess fx risk at 2 to 4 yr intervals Consider reiniti
By vgreene, 5 October, 2016 After 3 5y of initial bisphosphonate BP tx individualize ongoing tx based on comprehensive risk assessment NOF 6 ASBMR 12 AACE13
By vgreene, 5 October, 2016 If no fx before during tx hip BMD T score 2 5 no high fx risk nbsp nbsp ASBMR NOF 12 15 Consider d c of meds drug holiday nbsp nbsp ES 14 Temporarily d c BPs for up to 5y or longer depending on BMD and individual pt clinical circumstances nbsp nbsp AACE 1
By vgreene, 5 October, 2016 If hip BMD T score 2 5 high fx risk age 70 yo other strong fx risk factors FRAX score above country specific threshold6 12 Continue tx ES14 consider continued BP tx for up to 10y or change to alternative tx NOF 6 ASBMR12
By vgreene, 5 October, 2016 If hip spine multiple other osteoporotic fx before during tx Continue BP tx or change to alternative tx NOF 6 ASBMR12
By vgreene, 5 October, 2016 F u at least annually while on meds 1 yr f u while on GC tx ACOG1 check bone turnover markers CTX NTX BSAP OC PINP 2 3 6mo after initiation NOF 3 AACE4 check BMD q1 2y ACOG 1 NOF 3 AACE 4 ACR5 repeat screen 2y after initial screening 1 individualize tx du
